Clinical trial
A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in…
NCT00000833 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000833 |
|---|---|
| Title | A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. |
| Official title | A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Ribavirin, Didanosine |
| Enrollment | 20 |
| Completion | Jul 1, 1998 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 28, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: